Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Tisagenlecleucel Reinfusion in B-ALL
NCT05310591Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Assistance publique - Hôpitaux de Paris. Started Mar 2023; status: recruiting.
02
Drugs
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05310591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310591.